Phaseline

Companies › Whitehawk Therapeutics

Whitehawk Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HWK-016
MUCIN-16-targeted antibody-drug conjugate
MUC16Phase 1PROCFeb 2028
HWK-007
PTK7-directed antibody-drug conjugate
PTK7Phase 1Endometrial CancerOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07470853HWK-016Phase 1PROCOncologyFeb 2028
NCT07444814HWK-007Phase 1Endometrial CancerOncologyOct 2028

From the company's SEC filings

Cash and short-term investments of $170m on 2026-09-30; operating cash outflow about $76m a year; runway about 27 months at that burn, to Dec 2028

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PTK7 (1) MUC16 (1)

Companies with the same targets

IDEAYA Biosciences Day One Biopharmaceuticals Kivu Bioscience CanariaBio Beijing Biotech Regeneron Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.